ClinicalTrials.gg
CompletedNCT05190159Updated Sep 23, 2022

Monster Screw System Post-Market Clinical Follow-Up Study

An observational study in Ankle Injuries and Foot Injury, sponsored by Paragon 28. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2022-09-23.

Sponsored by Paragon 28 (part of Zimmer Biomet) · Observational

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
82
Sex
All
01

Study summary

Post-market clinical follow-up study on the Monster Screw System

Read the detailed description

Ambispective, multi-surgeon, single site, consecutive case series to determine the safety, performance, and benefits of the Monster Screw System.

02

Conditions studied

  • Ankle Injuries
  • Foot Injury
03

In context

Ankle Injuries

350 studies on the registry are indexed under Ankle Injuries; 74 are open to participants now.

This study's enrollment of 82 is close to the median of 84 across 73 observational studies indexed under Ankle Injuries.

Browse Ankle Injuries studies →

Lead sponsor

Paragon 28 is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

First submitted before Paragon 28 became part of Zimmer Biomet.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The investigational population will include subjects who have undergone a foot and/or ankle procedure that fulfill the eligibility criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject has undergone a foot and/or ankle procedure using the Monster Screw System and completed by one of the investigators.
  • The subject has adequate radiographic and medical records

For the Prospective Data Collection:

  • The subject is willing to provide written

Exclusion criteria

Exclusion Criteria:

-None

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
82 participants (actual)
Patient registry
No

Groups and cohorts

  • Monster Screw System

    Device: Monster Screw System

Interventions

  • DeviceMonster Screw System

    Subjects who have undergone a foot and/or ankle procedure involving the index device

06

What researchers measure

Primary outcomes

  1. Incidence of secondary procedures

    Safety will be assessed by recording the incidence of secondary procedures related to the index procedure

    Time frame: Up to 9 months

  2. Incidence of adverse events

    Safety will be assessed by recording the incidence of adverse events

    Time frame: Up to 9 months

Secondary outcomes

  1. Rate of Nonunion

    Safety as related to the rate of nonunion of the area treated with the index device

    Time frame: Up to 9 months

  2. Rate of Maintenance of Correction

    Safety as related to the rate of the maintenance of correction

    Time frame: Up to 9 months

  3. Rate of Index Device Failure

    Safety as related to the rate of the failure of the index device

    Time frame: Up to 9 months

  4. Foot and Ankle Mobility Measure

    Device performance and benefits as related to Foot and Ankle Mobility Measure Activities of Daily Living (0-84) subscale and current level of daily activity rating (0-100). The higher the score, the higher the level of function, with 100% representing no dysfunction.

    Time frame: Up to 54 months

  5. Visual Analog Scale

    Device performance and benefits as related to pain levels based on the Visual Analog Scale (range: 0 to 100; 0 = no pain; 100 = worst pain imaginable)

    Time frame: Up to 54 months

  6. Patient satisfaction

    Device performance and benefits as related to patient satisfaction (very satisfied, good, fair, not satisfied)

    Time frame: Up to 54 months

07

Study locations

1 site
  • Henry Ford Health Systems
    Jackson, Michigan 49201, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Sep 2022, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2021
First posted
Jan 13, 2022
StartActual
Jan 26, 2022
Primary completionActual
Sep 14, 2022
CompletionActual
Sep 21, 2022
Last update
Sep 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05190159
Lead sponsor
Paragon 28
Responsible party
Sponsor
First posted
Jan 13, 2022
Start date
Jan 26, 2022
Primary completion
Sep 14, 2022
Completion
Sep 21, 2022
Last update
Sep 23, 2022

Study contacts

Jacy Legue
study director · Paragon 28

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion